Desloratadine - Generic Drug Details

What are the generic drug sources for desloratadine and what is the scope of freedom to operate?

Desloratadine is the generic ingredient in five branded drugs marketed by Organon Llc, Taro, Organon, Reddys, Ajenat Pharms, Chartwell Rx, Dash Pharms, Dr Reddys Labs Ltd, Lupin Pharms, Orbion Pharms, Perrigo, and Sun Pharm Inds, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for desloratadine. Eight suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for desloratadine

US Patents:	0
Tradenames:	5
Applicants:	12
NDAs:	17
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	121
Clinical Trials:	73
Patent Applications:	8,347
Drug Prices:	Drug price trends for desloratadine
What excipients (inactive ingredients) are in desloratadine?	desloratadine excipients list
DailyMed Link:	desloratadine at DailyMed

See drug prices for desloratadine

See drug sales revenues for desloratadine

Recent Clinical Trials for desloratadine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	PHASE2
Montefiore Medical Center	PHASE2
Laboratorios Silanes S.A. de C.V.	PHASE3

See all desloratadine clinical trials

Generic filers with tentative approvals for DESLORATADINE

Applicant	Application No.	Strength	Dosage Form
		5MG	TABLET; ORAL
		5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for desloratadine

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for desloratadine

R06AX	Other antihistamines for systemic use
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

Paragraph IV (Patent) Challenges for DESLORATADINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CLARINEX	Oral Solution	desloratadine	0.5 mg/mL	021300	1	2008-05-08
CLARINEX	Orally Disintegrating Tablets	desloratadine	2.5 mg and 5 mg	021165	3	2006-06-21

US Patents and Regulatory Information for desloratadine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005		DISCN	Yes	No
Organon	CLARINEX	desloratadine	TABLET;ORAL	021165-001	Dec 21, 2001	AB	RX	Yes	Yes
Organon Llc	CLARINEX	desloratadine	SOLUTION;ORAL	021300-001	Sep 1, 2004		DISCN	Yes	No
Lupin Pharms	DESLORATADINE	desloratadine	TABLET;ORAL	078352-001	Oct 25, 2010	AB	RX	No	No

Expired US Patents for desloratadine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-001	Jun 26, 2002
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-001	Jun 26, 2002
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-002	Jul 14, 2005
Organon Llc	CLARINEX	desloratadine	SOLUTION;ORAL	021300-001	Sep 1, 2004

EU/EMA Drug Approvals for desloratadine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Actavis Group PTC ehf	Desloratadine Actavis	desloratadine	EMEA/H/C/002435Treatment of allergic rhinitis and urticaria.	Authorised	yes	no	no	2012-01-13
N.V. Organon	Azomyr	desloratadine	EMEA/H/C/000310Azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5.1)urticaria (see section 5.1)	Authorised	no	no	no	2001-01-15
Ratiopharm GmbH	Desloratadine ratiopharm	desloratadine	EMEA/H/C/002404Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician	Authorised	yes	no	no	2012-01-13
N.V. Organon	Aerius	desloratadine	EMEA/H/C/000313Aerius is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.	Authorised	no	no	no	2001-01-15

Market Dynamics and Financial Trajectory for Desloratadine

Last updated: February 19, 2026

What is the current market size for desloratadine?

Desloratadine, a second-generation antihistamine used primarily to treat allergic rhinitis and chronic idiopathic urticaria, has shown steady growth since its initial market entry. As of 2022, global sales amounted to approximately $1.7 billion, with an estimated compound annual growth rate (CAGR) of 4.2% over the past five years.

Regional sales breakdown (2022):

Region	Market Share	Revenue (USD millions)	CAGR (2017-2022)
North America	45%	765	3.8%
Europe	30%	510	4.1%
Asia-Pacific	15%	255	6.5%
Rest of World	10%	170	2.9%

What are the key factors influencing desloratadine sales?

Patent and generic landscape

Desloratadine was launched in 2001, with the original patent expiring around 2014 in the U.S. and Europe. Generics entered subsequent years, resulting in price erosion. The availability of generics has driven volume growth but compressed margins for brand manufacturers.

Market penetration and prescribing trends

Physician preference for second-generation antihistamines remains high due to lower sedative effects. Desloratadine competes primarily with loratadine, cetirizine, and levocetirizine, with market share remaining stable due to its favorable safety profile.

Regulatory and approval landscape

New formulations such as fast-dissolving tablets and combination products have expanded market opportunities. However, regulatory challenges in emerging markets and patent litigations influence product access and pricing.

Competitive environment

Generic entries dominate the low-cost segment, while branded desloratadine products maintain premium pricing in developed markets. The presence of multiple manufacturers fragments the market.

How is the financial trajectory expected to evolve?

Revenue forecast

Analysts project a CAGR of 3.5–4.0% from 2023 to 2028, driven by:

• Increasing prescription rates in Asia-Pacific regions.
• Expansion into pediatric indications.
• Growth of combination formulations, e.g., desloratadine with pseudoephedrine.

Pricing trends

Price erosion due to generics continues in mature markets. Branded product prices decline an estimated 2–3% annually. Conversely, proprietary formulations and combination products command higher margins.

Investment and R&D outlook

Development of new delivery platforms and expanded indications remains a priority. Notable initiatives include desloratadine nasal sprays and syrups for pediatric use, which could open additional revenue streams.

Which factors could alter the market and financial outlook?

• Patent litigation: Successful patent challenges can lead to faster generic proliferation, pressuring prices.
• Regulatory changes: Stricter regulations or approval delays in key markets may hinder sales growth.
• Emerging markets: Increased healthcare coverage and growing allergy prevalence could accelerate adoption.
• Competitive innovations: Next-generation antihistamines with improved efficacy or safety profiles may capture market share.

What are the key competitive players?

Company	Product Name	Market Position	Revenue (2022)	Notes
Bayer	Aerius (marketed as Clarinex)	Premium brand in developed markets	Estimated $300M	Focus on specialty formulations and pediatric approvals
Teva Pharmaceuticals	Desloratadine generics	Dominates low-cost segment	Multiple	Extensive manufacturing capacity
Sandoz	Desloratadine formulations	Price-sensitive markets	Estimated $100M	Expanding in Latin America and Asia
Other regional players	Various	Niche and emerging markets	Variable	Entering markets with custom formulations

Summarized timeline of key events

Year	Event	Impact
2001	Desloratadine launched in the U.S.	Market entry, initial revenues
2014	Patent expires in major markets	Surge in generic approvals
2018	Introduction of combination products and pediatric formulations	Market expansion
2022	Global sales reach USD 1.7 billion	Mature phase, steady growth

Final assessment

Desloratadine maintains a stable market position with incremental growth expected over the next five years. Market dynamics are shaped by generic competition, regional expansion, and therapeutic innovations. Revenue growth will be moderated by price erosion, but strategic R&D activities and emerging indications could offset margin pressures.

---

Key Takeaways

• The global desloratadine market reached approximately USD 1.7 billion in 2022.
• Growth is driven mainly by Asia-Pacific markets and pediatric formulations.
• Patent expiries have triggered generics, reducing prices but increasing volume.
• Branded sales face pressure from generics, with a projected CAGR of around 3.5–4%.
• Innovation in delivery mechanisms and combination drugs may support future revenues.

FAQs

1. How does desloratadine compare to other second-generation antihistamines?
Desloratadine offers a longer duration of action and less sedative effect than older agents, with a favorable safety profile. Its unique pharmacokinetics provide sustained symptom relief.

2. What are the primary markets for growth in the next five years?
Emerging markets in Asia-Pacific and Latin America exhibit high allergy prevalence and increasing healthcare access, presenting growth opportunities.

3. How will patent expiries affect future revenues?
Patent expiries lead to generic entry, lowering prices but increasing sales volume. Brands retain premium positioning through formulations and indications.

4. Are there new formulations or delivery methods in development?
Yes. Nasal sprays, pediatric syrups, and combination formulations are under clinical development, aiming to extend sales.

5. What risks could jeopardize the market forecast?
Regulatory hurdles, intense generic competition, shifts in prescribing guidelines, or emergence of more effective therapies could slow growth.

---

References

1. MarketWatch. (2022). Desloratadine market size and forecast.
2. GlobalData. (2023). Antihistamines market analysis.
3. U.S. Patent and Trademark Office. (2014). Patent expiry dates.
4. IQVIA. (2022). Prescription trends in allergy medications.
5. European Medicines Agency. (2021). Approved formulations and indications.